Capacidades de investigación y tecnológicasActualizado el 4 de mayo de 2026
Physicochemical Characterization of Nanomedicines
Communication Manager en NANBIOSIS-ICTS
Zaragoza, España
Acerca de
One of the causes that increases the time required to reach the market in nanotherapeutics is the preclinical validation. The standard protocols for more traditional drugs are not applicable for nanomedicines, starting with the study of the physicochemical properties of the nanomaterials. NANBIOSIS offers a complete study plan tailored to meet the demands of each nanomedicine product, from the properties of the materials all the way to their preclinical validation. This is developed in collaboration with the user and starting from a set of basic analytical tests to more sophisticated experiments. Also, some of them are available under GLP for regulatory purposes.
Description
We offer a complete Physicochemical Characterization. e.g., size distribution, composition, purity, surface characteristics, stability, and more adapted to the different products by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter.
More info: https://www.nanbiosis.es/physicochemical-characterization-of-nanomedicines/
Tipo
- Enfermedades infecciosas
- Sistema nervioso central
- Detección de sustancias
- Enzimas
Organización
Valencia, España
Oportunidades similares
Capacidades de investigación y tecnológicas
In vitro Characterization of Nanomedicines
- Inmunología
- Enfermedades infecciosas
Gabriel Alfranca
Communication Manager en NANBIOSIS-ICTS
Zaragoza, España
Capacidades de investigación y tecnológicas
In vivo Characterization of Nanomedicines
- Oncología
- Inmunología
- Enfermedades infecciosas
- Sistema digestivo y hepatología
- Enfermedades cardiovasculares y sistema circulatorio
Gabriel Alfranca
Communication Manager en NANBIOSIS-ICTS
Zaragoza, España
Capacidades de investigación y tecnológicas
Biofunctionalized Nanoconjugates: Design, Production, and Characterization
- Detección de sustancias
- Sistema nervioso central
- Sangre y sistema linfático
- Enfermedades cardiovasculares y sistema circulatorio
Gabriel Alfranca
Communication Manager en NANBIOSIS-ICTS
Zaragoza, España